csl362
mAbexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2012 (NCT01632852)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-3 receptor subunit alphaINHIBITOR
IL3RA inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- csl362
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01632852 | Phase 1 | Jul 1, 2012 | CSL, CSL Behring, Parexel |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| CSL | For profit | 1 | 1 | 1 | 2012 |
| CSL Behring | For profit | 1 | 0 | 1 | 2012 |
| Parexel | For profit | 1 | 0 | 1 | 2012 |
3 organizations
Page 1 / 1